SARS-CoV-2 infections in patients enrolled on the Children's Oncology Group standard-risk B-cell acute lymphoblastic leukemia trial, AALL1731.

Creator(s)

Caitlin W. Elgarten
John A. Kairalla
Joel Thompson, Children's Mercy HospitalFollow
Tamara P. Miller
Cindy Wang
Susan Conway
Mignon L. Loh
Elizabeth A. Raetz
Sumit Gupta
Rachel E. Rau
Anne Angiolillo
Karen R. Rabin
Sarah Alexander

Document Type

Article

Publication Date

8-2023

Identifier

DOI: 10.1002/jha2.697; PMCID: PMC10435702

Abstract

Hematologic malignancy is a risk factor for severe coronavirus disease 2019 (COVID-19) in adults; however, data specific to children with leukemia are limited. High-quality infectious adverse event data from the ongoing Children's Oncology Group (COG) standard-risk B acute lymphoblastic leukemia/lymphoma (ALL/LLy) trial, AALL1731, were analyzed to provide a disease-specific estimate of SARS-CoV-2 infection outcomes in pediatric ALL. Of 253 patients with reported infections, the majority (77.1%) were asymptomatic or mildly symptomatic (CTCAE grade 1/2) and there was a single COVID-19-related death. These data suggest SARS-CoV-2 infection does not confer substantial morbidity among young patients with B-lymphoblastic leukemia/lymphoma (B-ALL/LLy).

Journal Title

EJHaem

Volume

4

Issue

3

First Page

745

Last Page

750

Keywords

B‐ALL; SARS‐CoV‐2; pediatrics

Comments

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Publisher's Link: https://onlinelibrary.wiley.com/doi/10.1002/jha2.697

Recommended Citation

Elgarten CW, Kairalla JA, Thompson JC, et al. SARS-CoV-2 infections in patients enrolled on the Children's Oncology Group standard-risk B-cell acute lymphoblastic leukemia trial, AALL1731. EJHaem. 2023;4(3):745-750. Published 2023 May 10. doi:10.1002/jha2.697